Celltrion Pharm Current Valuation vs. Revenue
| 068760 Stock | KRW 56,700 600.00 1.07% |
For Celltrion Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Celltrion Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Celltrion Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Celltrion Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Celltrion Pharm over time as well as its relative position and ranking within its peers.
Celltrion |
Celltrion Pharm Revenue vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Celltrion Pharm's current stock value. Our valuation model uses many indicators to compare Celltrion Pharm value to that of its competitors to determine the firm's financial worth. Celltrion Pharm is the top company in current valuation category among its peers. It also is the top company in revenue category among its peers totaling about 0.07 of Revenue per Current Valuation. The ratio of Current Valuation to Revenue for Celltrion Pharm is roughly 14.71 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Celltrion Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Celltrion Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Celltrion Current Valuation vs. Competition
Celltrion Pharm is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 11.73 Trillion. Celltrion Pharm totals roughly 5.87 Trillion in current valuation claiming about 50% of equities under Health Care industry.
Celltrion Revenue vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Celltrion Pharm |
| = | 5.87 T |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Celltrion Pharm |
| = | 398.74 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Celltrion Revenue vs Competition
Celltrion Pharm is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 797.48 Billion. Celltrion Pharm totals roughly 398.74 Billion in revenue claiming about 50% of equities under Health Care industry.
Celltrion Pharm Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Celltrion Pharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Celltrion Pharm will eventually generate negative long term returns. The profitability progress is the general direction of Celltrion Pharm's change in net profit over the period of time. It can combine multiple indicators of Celltrion Pharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.
Celltrion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Celltrion Pharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Celltrion Pharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Celltrion Pharm's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Celltrion Pharm without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your Celltrion Pharm position
In addition to having Celltrion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Celltrion Stock
To fully project Celltrion Pharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Celltrion Pharm at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Celltrion Pharm's income statement, its balance sheet, and the statement of cash flows.